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Abstract 25 
Guidance on dissolution testing for parenteral formulations is limited and not often related in 26 
vivo performance. Critically ill patients represent a target cohort, frequently 27 
hypoalbuminaemic, to whom certain parenteral formulations are administered. Amphotericin 28 
B (AmB) is a poorly soluble, highly protein-bound drug, available as lipid-based formulations 29 
and used in critical illness. The aim of this study was to develop media representing 30 
hypoalbuminaemic and healthy plasma, and to understand and simulate the dissolution profile 31 
of AmB in biorelevant media. Dissolution media were prepared with bovine serum albumin 32 
(BSA) in Krebs-Ringer buffer, and tested in a flow through cell apparatus and a bottle/stirrer 33 
setup. Drug activity was tested against Candida albicans. BSA concentration was positively 34 
associated with solubility, degradation rate and maximum amount dissolved, and negatively 35 
associated with dissolution rate constant and antifungal activity. In the bottle/stirrer setup, a 36 
biexponential model successfully described simultaneous dissolution and degradation, and 37 
increased in agitation reduced the discriminatory ability of the test. The hydrodynamics 38 
provided by the flow-through cell apparatus was not adequate to dissolve the drug. Establishing 39 
discriminating test methods with albumin present in the dissolution media, representing the 40 
target population, supports future development of biorelevant and clinically relevant tests for 41 
parenteral formulations. 42 
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1. Introduction 47 
The parenteral administration route is utilized when a quick or a depot effect is needed, when 48 
the patient cannot take oral formulations for systemic therapy or when the physicochemical 49 
properties of the drug make it impossible to be delivered by any other route [1]. Formulations 50 
such as microspheres, liposomes, nanoparticles and emulsions (among others) have been 51 
developed to be able to meet the requirements of a long or a sustained exposure. The dissolution 52 
test is an in vitro test designed to characterize the dissolution/release of the drug from a 53 
formulation and hopefully, predict the behaviour of the drug in vivo. There are 3 main methods 54 
to assess dissolution/release from controlled release parenterals that have been described 55 
extensively in the literature: Sample and separate, Continuous flow and Dialysis methods [2-56 
6].  57 
Several factors may influence the dissolution of a formulation in vivo. As the ultimate goal of 58 
the dissolution test is to ensure clinical performance, these factors should be reflected in the 59 
dissolution test [7]. Biorelevant dissolution testing takes into consideration the characteristics 60 
of the site of administration in vivo that may impact on the dissolution and release of a drug 61 
from a formulation. This involves the composition and the physicochemical properties of the 62 
medium and the hydrodynamics where the drug will be released [8]. 63 
For parenterals administered intravenously the release medium is blood, consisting of 2 64 
fractions, the cellular fraction and plasma. Plasma is a fluid that contains ions and 65 
biomolecules. Albumin is the major circulating protein in human plasma (up to the 60% of 66 
plasma proteins). The normal reference value of plasma albumin for a healthy subject is 40 g/L 67 
± 10% [9]. Albumin is the most relevant protein in terms of drug administration as it is a carrier 68 
for metals, ions, fatty acids, amino acids, bilirubin, enzymes and drugs [9].  69 
Several parenteral formulations, that are not simple aqueous solutions, can be administered in 70 
the clinical setting to patients that have significant morbidities such as cancer or critically 71 
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illness. Hypoalbuminaemia is common in the critical ill patients (affecting approximately 50% 72 
of patients), and while there is no reference value for hypoalbuminaemia, it can be considered 73 
when the plasma albumin levels are lower than < 25 g/L [9]. Low levels of serum albumin may 74 
affect pharmacokinetics and pharmacodynamics of highly protein bound drugs. With a 75 
decrease in the protein levels in plasma there is more unbound drug in circulation which would 76 
lead to an increased pharmacological effect. On the other hand, the free drug can penetrate into 77 
tissues with a corresponding increase in the volume of distribution and a subsequent decrease 78 
in the maximum plasma concentration. [9, 10]. Release/dissolution of poorly soluble, highly 79 
protein bound drugs from parenteral formulations, and associated local drug concentrations are 80 
likely to be influenced by protein concentration at the site of release. Therefore, in vitro 81 
dissolution tests that simulate the in vivo environment are needed for parenteral formulations 82 
that are not aqueous solutions, which take into account the likely changes that arise in target 83 
patient groups, with particular reference to albumin concentration. 84 
One drug that is administered to critically ill patients is Amphotericin B (AmB), which is still 85 
one of the most effective therapies for systemic fungal infections. In clinical practice, AmB is 86 
administered as an infusion using a multidose scheme usually lasting for several days [11]. 87 
AmB is highly bound (>95%) to plasma proteins (Low Density Lipoproteins, albumin and α1 88 
glycoproteins [12, 13]). The major drawback of AmB is its poor water solubility (reported 89 
values: 0.09 µg/mL [14], 1.38 µg/mL [15] and 6 µg/mL [16] at pH = 7). To tackle this problem, 90 
several formulations have been developed, including Liposomal AmB (Ambisome®) and AmB 91 
in a lipid complex (Abelcet®), where AmB is within the lipid structures. Furthermore, a 92 
correlation has been observed between volume of distribution at steady state of total AmB 93 
following administration of Abelcet® and albumin concentration, in critically ill patients [17], 94 
illustrating the relevance of albumin concentration to AmB pharmacokinetics in the target 95 
patient cohort. 96 
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The aim of this study was to investigate the solubility and the dissolution of AmB in simulated 97 
plasma with albumin concentrations representing healthy subjects and hypoalbuminaemic 98 
patients, and to develop a mathematical model to describe and simulate all the processes 99 
involved in its dissolution, in order to be the basis for the development of biorelevant 100 
dissolution testing of AmB formulations. 101 
2. Materials and Methods 102 
2.1 Materials 103 
AmB analytical standard (87.8%), Methanol (MeOH) High Performance Liquid 104 
Chromatography (HPLC) grade, formic acid, Sabouraud Dextrose (SBD) Broth, NaOH, 105 
MgCl2, CaCl2, NHCO3 and NH4HCO2 were obtained from Sigma Aldrich (Germany); AmB 106 
active pharmaceutical ingredient (API) powder (85%) from Cayman Chemical (USA); Bovine 107 
Serum Albumin Protease Free Powder Fraction V (BSA), dimethyl sulfoxide (DMSO), 108 
dextrose, Na2HPO4, NaH2PO4, NaCl and KCl were obtained from Fisher Scientific (USA); 109 
Sabouraud dextrose (SBD) agar was obtained from Oxoid (UK), 25 mL sterile universal culture 110 
tubes were obtained from Sterilin Thermo Scientific (UK); 10 μL plastic loops from Microspec 111 
(UK); GF/D (pore size 2.7 μm, 25 mm diameter) and GF/F (pore size 0.7 μm, 25 mm diameter) 112 
filters were obtained from Whatman (UK) and regenerated cellulose (RC) filters 0.45 µm 13 113 
mm diameter from Cronus (UK). 114 
The yeast strain used in the microbiology experiments was Candida albicans SC5314 [18].  115 
 116 
2.2. Dissolution biorelevant media composition and characterization 117 
The dissolution media employed were Krebs-Ringer Buffer (KRB), supplemented with BSA 118 
at different concentrations according to the experiment: 1.5, 2, 3 or 4% w/v. The pH was 119 
adjusted to 7.2 – 7.3 with 0.1 M HCl using a Seven Compact pH meter (Mettler Toledo, China). 120 
The osmolality of the media with 2 and 4% w/v BSA was measured via the freezing-point 121 
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depression method with a Micro-Osmometer 3300 (Advanced Instruments, Massachusetts 122 
USA). Viscosity of all media was measured with a Bohlin Rheometer (Germany) with a shear 123 
rate 0.1 - 1.5 Pa (logarithmic scale), 20 integrations per measurement and with a delay time of 124 
5 seconds and an integration time of 20 seconds. The geometry was a 4° and 40 mm diameter 125 
(CP 4/40) cone parallel to a plate and the experiments were conducted at 25°C in triplicate. 126 
The measurement at the closest value to the steady state was recorded as the viscosity value.  127 
 128 
2.3. Chromatographic conditions for the analysis of AmB from biorelevant dissolution 129 
media samples 130 
The chromatographic method to quantify AmB was a modification of the method reported by 131 
Nilsson-Ehle et al [19]. Briefly, AmB was quantified by HPLC analysis using a Hewlett 132 
Packard Series 1100 equipped with an auto sampler, temperature regulated column 133 
compartment, quaternary pump and diode array detector (DAD detector) (Agilent 134 
Technologies). The column was a C18 Waters Sunfire Column (Ireland) 150 x 46 mm 5μm. 135 
The temperature of the column compartment was set at 25°C. The mobile phase consisted of 136 
formate buffer (50 mM; pH = 3.2): MeOH (25:75, v/v); the flow rate was 1 mL/min and 137 
analysis was performed with the DAD detector at λ = 406 nm. The UV spectrum was recorded 138 
from 300 to 450 nm (where necessary for detection of the degradant). Quantification of AmB 139 
in samples was made based on calibration curves. Freshly prepared standard solutions (0.5 – 140 
10 μg/mL) in the corresponding medium were prepared by appropriate dilution of a 500 μg/mL 141 
stock solution of AmB analytical standard in 1:1 MeOH: DMSO v/v. The 5 μg/mL standard 142 
solution in KRB – BSA 4% w/v was incubated at 37°C and was monitored every hour to check 143 
the stability of the samples for up to 24 h. The limit of detection and the limit of quantification 144 
were 0.12 and 0.37 μg/mL, respectively. 145 
 146 
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2.4. Sample treatment of AmB in the biorelevant dissolution media 147 
Proteins were precipitated by adding 2 volumes of methanol to 1 volume of the sample 148 
followed by mixing in a vortex (Scientific Industry Inc., USA) for 30 seconds and then 149 
centrifuged for 10 minutes at 12000 rpm and 5°C (Eppendorf Heraeus Fresco 17 centrifuge, 150 
Thermo Electron LED GmbH., Germany). The supernatant was filtered through a 0.45 μm RC 151 
filter before injected to the HPLC. 152 
 153 
2.5. Liquid chromatography – Mass Spectrometry (LCMS) studies 154 
The identification of the mass of the molecular structures detected as peaks in the HPLC 155 
chromatograms was performed by LCMS. An excess of AmB was added to the medium (KBR-156 
BSA 4% w/v) and after stirring for 8 h at 130 rpm [Variomag multipoint stirring plate (Thermo 157 
Electron Corporation, Germany); 15 x 6 mm magnetic stirrers (Fisherbrand, UK)] at 37°C, the 158 
undissolved drug was removed by centrifugation [3000 rpm 5 min 5°C]. The supernatant was 159 
treated for protein precipitation (section 2.4) and analysed by LCMS [Ultimate 3000 UHPLC 160 
(Dionex, USA); autosampler; quaternary pump; DAD detector; maXisHD Time-of-Flight 161 
Mass Spectrometer coupled with an electrospray source (ESI-TOF) (Bruker Daltonics, 162 
Germany)]. The conditions of the chromatography analysis were the same as previously 163 
described (section 2.3), with the exception of the injection volume being 30 μL and a split flow 164 
post column before the mass spectrometry detector to a flow rate of 0.3 mL/min. In this case, 165 
the formate buffer (50 mM) was prepared with formic acid and ammonium formate, in order 166 
to make it suitable for Mass Spectrometry (absence of sodium ions). The samples were 167 
analysed in negative mode. Data was processed using external calibration with the Bruker 168 
Daltonics software (DataAnalysisTM) as part of the overall hardware control software 169 
(CompassTM). 170 
 171 
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2.6. Degradation studies of AmB in the biorelevant dissolution media 172 
In order to characterise the degradation of AmB in the dissolution media, approximately 10 mg 173 
of AmB API powder was added to 50 mL of the dissolution media (KRB-BSA 1.5, 2, 3, or 4% 174 
w/v) and then stirred for 1 hour at 130 rpm (in Variomag multipoint stirring plate) at 37°C. The 175 
samples were centrifuged for 5 minutes at 3000 rpm and 4°C (Heraeus Biofuge Primo R 176 
Centrifuge, Thermo Electron LED GmbH. Germany) to remove the undissolved AmB and the 177 
supernatant was incubated at 37°C. Samples were taken at 0.5, 1, 1.5, 2, 3, 4, 5, 6 and 8 hours, 178 
injected to the HPLC after sample treatment (protein precipitation; section 2.4) and the 179 
concentration of AmB in the samples was calculated. All experiments were performed in 180 
triplicate. A linear fit was applied to the degradation data from 4 h to the last time point, after 181 
a natural logarithm transformation of the measured concentration (Excel 2013, Microsoft. 182 
USA) and the degradation rate constant (𝑘𝑑𝑒𝑔) was calculated from the slope of the line.  183 
  184 
2.7. Solubility studies of AmB in the biorelevant dissolution media 185 
Approximately 2.5 mg of AmB API powder were placed in a 100 mL glass bottle (56 mm 186 
diameter/ 105 mm height; Duran, Germany) with 30 mL of KRB supplemented with BSA 1.5, 187 
2, 3 or 4% w/v, stirred at 130 rpm (in Variomag multipoint stirring plate) and incubated at 188 
37°C. The sampling times were 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours. The undissolved 189 
AmB was removed by centrifugation (Eppendorf centrifuge 3000 rpm, 5 min, 5°C; following 190 
validation (data not shown) centrifugation was selected as a cost-effective alternative to 191 
filtration) and after sample treatment (protein precipitation; section 2.4), the samples were 192 
injected to the HPLC and the concentration of AmB in the samples was calculated. All 193 
experiments were performed in triplicate. 194 
 195 
2.8 Mass balance studies of AmB in the biorelevant dissolution media 196 
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The total undissolved, dissolved and degraded percentages of AmB in KRB-BSA 2% and 4% 197 
w/v media were calculated. Approximately 0.3 mg of the AmB API powder were weighed on 198 
a micro balance (Sartorius SE 2-F connected to an Eliex E550 antistatic device). The AmB was 199 
placed in a 100 mL glass bottle containing 15 mL of dissolution medium (KRB with 2 or 4% 200 
w/v BSA), and then stirred at 130 rpm and incubated at 37°C. A 1 mL sample withdrawn at 24 201 
h was centrifuged (3000 rpm, 5 min, 5°C; removal of the undissolved AmB), and after addition 202 
of methanol for the protein precipitation (section 2.4), was injected to the HPLC and the AmB 203 
concentration (𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ) was calculated. The remaining AmB in the bottle was 204 
dissolved with methanol (protein precipitation procedure; section 2.4), analysed and the final 205 
concentration of AmB (𝐴𝑚𝐵 𝑓𝑖𝑛𝑎𝑙) was calculated. All experiments were performed in 206 
triplicate. 207 
The total undissolved (𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑: AmB undissolved powder in the bottle), the total 208 
dissolved (𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑: AmB in solution at 24 h and AmB degraded up to 24 h) and the 209 
total degraded (𝐴𝑚𝐵 𝑇𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑 : AmB degraded up to 24 h) percentages of AmB were 210 
calculated based on Eq (1-3): 211 
𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑  = 𝐴𝑚𝐵 𝑓𝑖𝑛𝑎𝑙 − 𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ  Eq 1 212 
𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑  = 𝐴𝑚𝐵 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − 𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑   Eq 2 213 
where 𝐴𝑚𝐵 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 is the mass (0.3 mg) placed into the reservoir initially (100%)  214 
𝐴𝑚𝐵 𝑇𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑  = 𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑  −  𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ  Eq 3 215 
 216 
2.9. Antimicrobial activity assay of AmB in the biorelevant media: MIC and MFC 217 
determination 218 
2.9.1. Quantification of C. albicans. The strain was maintained on SBD agar plates. A new 219 
culture was started from a single colony in a culture tube with 5 mL of SBD broth and was 220 
incubated at 37°C overnight in a shaking incubator (Innova 44, New Brunswick Scientific, 221 
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USA), after which the optical density (OD) was measured at 600 nm (OD600). The Colony 222 
Forming Units (CFU) of the culture was determined by preparing serial dilutions from 10–1 to 223 
10–6. 100 μL of the suspensions were plated on SBD agar plates, incubated overnight at 37°C, 224 
the number of colonies were counted and the relationship with the OD600 of the culture was 225 
established.  226 
2.9.2 MIC and MFC studies: The OD600 of an overnight culture of C. albicans was measured, 227 
and diluted to a final concentration of 105 CFU/mL. Minimum Inhibitory Concentration (MIC) 228 
studies were performed with the following concentrations of AmB: 0, 1.5, 3, 4.5, 6, 7.5, 9 and 229 
10.5 μg/mL for the experiments with BSA 2% w/v, and 0, 3, 4.5, 6, 7.5, 9, 10.5 and 12 μg/mL 230 
for the experiments with BSA 4% w/v. Culture medium without BSA was set as the control for 231 
these experiments. The MIC was defined as the lowest concentration of AmB at which there 232 
was no visual turbidity in the liquid broth. The Minimum Fungicidal Concentration (MFC) 233 
experiments were performed by plating 10 μL of the yeast cultures from the MIC assays on 234 
SBD agar plates and incubated for 24 h at 37°C. The MFC was defined as the lowest 235 
concentration of AmB where there was no visible growth on the agar plates. The results are 236 
expressed as the intervals where the MIC and MFC were found. The experiments were 237 
performed in duplicate. 238 
 239 
2.10 Dissolution studies of AmB in biorelevant media:  240 
2.10.1 Sample and separation method (bottle/stirrer) 241 
Dissolution studies were carried in a glass bottle with a similar setup as the solubility 242 
experiments (section 2.7). 0.5 mg of AmB API powder was weighed and placed into a 100 mL 243 
glass bottle with 30 mL of the dissolution medium. Two hydrodynamic conditions were tested: 244 
low agitation (130 rpm) for KRB – BSA 0, 1.5, 2, 3 and 4% w/v and high agitation (380 rpm) 245 
for experiments with KRB – BSA 2% w/v and BSA 4% w/v. Samples withdrawn up to 24h 246 
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were treated and analysed as previously described (sections 2.7 and 2.4) and the % AmB 247 
dissolved over time was calculated. All experiments were performed in triplicate. 248 
2.10.2 Continuous Flow method (flow through cell apparatus) 249 
The dissolution studies were carried out in a flow-through cell dissolution apparatus (Sotax 250 
CE7 smart connected to a Sotax piston pump CP7, Sotax, Switzerland) operated in the closed 251 
mode [20]. A 5mm ruby glass bead was positioned at the bottom of the cell (small cell:12 mm 252 
diameter; large cell: 22.6 mm diameter), the conical part of the cell was filled with 1 mm glass 253 
beads and 5 mg of AmB API powder were weighed and placed on top of the glass beads. Glass 254 
fibre filters (GF/D, GF/F) were positioned at the top of the cell. Two different hydrodynamic 255 
conditions were tested: i. small cell with a flow rate of 35 mL/min (high velocity) and ii. large 256 
cell with a flow rate of 16 mL/min (low velocity). 50 mL of the dissolution medium (KRB with 257 
BSA 2% w/v or 4% w/v) were put in the reservoir under constant stirring. 0.5 mL samples were 258 
collected at specific time points up to 8 hours and volume replacement with fresh medium was 259 
made. Dissolution experiments were also performed with 0.5 mg of AmB in the two media 260 
(KRB with BSA 2% w/v or 4% w/v) under both velocity conditions and with 5 mg of AmB 261 
API in water (HPLC grade) under high velocity conditions. The samples after treatment 262 
(protein precipitation; section 2.4) were injected to the HPLC and the % AmB dissolved over 263 
time was calculated. All experiments were performed in triplicate at 37°C.  264 
 265 
2.11 Treatment of dissolution data 266 
The AmB dissolution profiles were corrected for degradation using the corresponding 267 
degradation rate constants (section 2.6). The concentration over time accounting for 268 
degradation (Ccorrected) was calculated using Eq 4. 269 
𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝐶𝑡 +  𝑘𝑑𝑒𝑔 ∗  𝐴𝑈𝐶0−𝑡  Eq 4. 270 
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Where Ct is the observed concentration at time t, AUC0-t is the Area Under the Observed 271 
Concentration – Time Curve from time 0 to time 𝑡 and 𝑘𝑑𝑒𝑔 is the degradation rate constant 272 
obtained from the degradation experiments.  273 
The corrected dissolution profiles were calculated based on 𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 and a first order curve 274 
fitting (Eq 5) was performed in order to obtain the dissolution rate constant (GraphPad Prism 275 
6, Graph Pad Software, Inc, USA). 276 
𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝑋𝑚𝑎𝑥 ∗ (1 − 𝑒
−𝑘𝑑𝑖𝑠𝑠𝑡)  Eq 5. 277 
where 𝑘𝑑𝑖𝑠𝑠is the dissolution rate constant, 𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 is the corrected percent dissolved at time 278 
t and 𝑋𝑚𝑎𝑥 is the maximum corrected percent dissolved. The goodness of fit was assessed 279 
based on the correlation coefficient (R2) and the Akaike Information Criterion (AIC). 280 
Equation 6 was utilized to simulate the dissolution profiles (𝑋𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑) in the bottle/stirrer 281 
accounting for degradation. The simulations were performed using GraphPad Prism 6. 282 
𝑋𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 =  
𝑋𝑚𝑎𝑥∗𝑘𝑑𝑖𝑠𝑠
𝑘𝑑𝑖𝑠𝑠−𝑘𝑑𝑒𝑔
(𝑒−𝑘𝑑𝑒𝑔𝑡 − 𝑒−𝑘𝑑𝑖𝑠𝑠𝑡)   Eq 6. 283 
Where 𝑋𝑚𝑎𝑥 is the maximum corrected percent dissolved, 𝑘𝑑𝑖𝑠𝑠 is the dissolution rate constant 284 
and 𝑘𝑑𝑒𝑔 is the degradation rate constant. 285 
 286 
2.12 Statistical analysis 287 
Data were analysed with one-way ANOVA and the Tukey test was selected in order to perform 288 
pair wise multiple comparison of all groups (significance p<0.05).  289 
A t- test was used to compare two experimental means (significance p < 0.05). The analyses 290 
were performed with Statgraphics Centurion XVII (Statpoint Technologies Inc, USA). 291 
 292 
3. Results and Discussion 293 
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3.1 Biorelevant dissolution media simulating healthy and hypoalbuminaemic parenteral 294 
conditions 295 
The composition of KRB and its physicochemical properties are similar to human plasma 296 
(Table 1). The biorelevance of KRB supplemented with BSA is described in terms of 297 
composition, pH, osmolality and viscosity as compared with the corresponding properties of 298 
human plasma from healthy subjects (Table 1). [21, 24]. A small variation in pH is observed 299 
due to the pH adjustment before the addition of the proteins. The addition of BSA marginally 300 
increases the viscosity of the medium (p<0.01) whereas the increase of the osmolality is not 301 
statistically significant (p > 0.05). The BSA concentration in the medium (1.5 - 4 % w/v) 302 
reflects the albumin levels in the plasma of a critically ill patient and of a healthy subject [9]. 303 
A 76% sequence identity between Human Serum Albumin (HSA) and Bovine Serum Albumin 304 
has been measured [25], justifying the use of BSA as a substitute for HSA. In addition, an in 305 
silico analysis utilizing molecular modeling, predicted only one favourable binding site in both 306 
HSA and BSA for AmB B [26], further supporting the biorelevance of KRB supplemented 307 
with BSA.  308 
 309 
3.2. Identification of the AmB degradation product 310 
During the development of the AmB quantification method, an extra peak in AmB 311 
chromatograms with a shorter retention time was noted. When the sample was incubated at 312 
37°C, the area of this unknown peak increased with time and the AmB peak area decreased. 313 
The UV spectra of the two peaks are broadly similar with a main difference in the λmax [λmax 314 
for AmB: 406 nm; λmax for unknown compound: 380 nm (Figure 1)], suggesting that the 315 
unknown compound is related to AmB. LCMS experiments revealed that the mass spectrum 316 
of the unknown compound has a difference in mass (corresponding to a chlorine adduct) 317 
compared to the mass of AmB (Figure 2). Based on these studies, this unknown compound is 318 
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more polar than AmB (due to its shorter retention time) and it can be suggested that it is AmB’s 319 
degradation product (deg-AmB). It has been reported that AmB auto-oxidates in the presence 320 
of oxygen with formation of free radicals and epoxidation is the most probable route of 321 
degradation (but the epoxidation products have not yet been characterized) [27 - 29]. A 322 
degradation product has not been reported previously in studies where AmB was quantified. 323 
This could be due to the specific ion transition followed by the multiple reaction monitoring 324 
[30-33] and the elution of the more polar AmB degradation product in the washing step of the 325 
solid phase extraction used for the purification of the sample [31, 34-36] in these methods. 326 
Furthermore, plasma components could potentially prevent/alter the rate of AmB degradation.  327 
 328 
3.3. Degradation studies of AmB in the biorelevant media 329 
The degradation of AmB in dissolution media with different concentrations of BSA was 330 
assessed in order to enable the quantification of the actual AmB dissolved in the dissolution 331 
studies. Degradation data and degradation rate constants of AmB in the studied media are 332 
presented in Figure 3 and Table 2, respectively. The concentration of BSA in the medium has 333 
a statistically significant effect on the degradation rate constants of AmB (p<0.01). The 334 
increasing concentration of BSA results in an increase in the degradation rate constant of AmB, 335 
with the degradation rate constant being 3 times higher in the media with 4% w/v BSA 336 
compared to the one in media with BSA 1.5% w/v. 337 
 338 
3.4. Solubility studies of AmB in the biorelevant media 339 
The AmB solubility data for 24 h in KRB with different concentrations of BSA are presented 340 
in Figure 4. The solubility of AmB in the biorelevant media increases with an increase in BSA 341 
concentration in the medium. While drug loss through degradation facilitates further 342 
solubilisation, as the dissolution rate is faster than the degradation rate, the AmB solubility 343 
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saturation value is considered to be the point at which the concentration reaches a plateau, 344 
generally at around 10 – 12 hours (3 – 5 h for KRB BSA 1.5% w/v) (Table 2) and after this 345 
point, the AmB concentration is decreased due to degradation being the dominant process at 346 
this time when there is no longer the same excess of the drug. The deg-AmB peak was present 347 
in all samples’ chromatograms and its area increased with increased mass dissolved. The 348 
increase in drug solubility mediated by albumin has been reported for another anti-fungal drug, 349 
Itraconazole, illustrating the importance of BSA concentration in the medium for poorly 350 
soluble, highly protein bound drugs [37]. These solubility values should be taken into account 351 
when developing biorelevant test conditions for an AmB formulation, with a view to 352 
developing an in vivo / in vitro correlation. As the patients who are going to receive AmB 353 
therapy may present with hypoalbuminaemia, albumin concentration could impact on the 354 
observed mass dissolved/released from the formulation, which will be reflected in the 355 
pharmacokinetics of the drug.  356 
 357 
3.5. Mass Balance studies of AmB in the biorelevant media 358 
The results of the mass balance studies of AmB in KRB with BSA 2% w/v and KRB with BSA 359 
4% w/v are presented in Table 3. The 𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ is similar for both 360 
concentrations of BSA (2% w/v and 4% w/v) in the medium, but the 𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 in which 361 
the degradation of AmB is taken into account is higher in the medium with BSA 4% w/v, as 362 
the AmB degradation is higher in this BSA concentration. This supports the results in sections 363 
3.3 and 3.4, implying that BSA has a critical effect on the degradation and solubility of AmB 364 
in the medium, confirming the faster degradation and increased mass dissolved in medium with 365 
higher BSA concentration. 366 
 367 
3.6. Antimicrobial activity of AmB in the biorelevant media 368 
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In order to assess the effect of BSA in the activity of AmB against Candida albicans, MIC and 369 
MFC values were determined (Table 4). A marked effect of BSA on the activity of AmB is 370 
shown. The results for the control experiments are in agreement with what is reported in the 371 
literature for the MIC of AmB against C. albicans (0.06 – 1 mg/L) [36-39]. When BSA was 372 
added to the culture media, the MIC increased 10-fold in the medium with BSA 2% w/v and 373 
approximately 20-fold in the medium with BSA 4% w/v. In the absence of BSA, the MFC was 374 
fairly close to the MIC values, indicating that AmB is fungicidal. However, in the presence of 375 
BSA, the MFC was higher than the highest concentration of AmB that was tested, suggesting 376 
a fungistatic activity instead. The increase in the concentration of AmB to exert its antifungal 377 
activity has been reported before in studies where the source of albumin was HSA (human 378 
serum albumin) [40]. This could be explained by the fact that AmB is highly bound to proteins, 379 
and only the free fraction can exert a pharmacological effect. If there is more albumin in the 380 
medium, more drug will be bound to it and the concentration required to have the same efficacy 381 
will be higher. In vivo, AmB can also be bound to α1-acid glycoprotein [12, 13], but as this 382 
protein’s blood concentration is only 0.1% w/v (24 μM) compared to the 2.0 - 4.0% w/v BSA 383 
(300 – 600 μM) (that is used to substitute HSA) its effect can be considered negligible for the 384 
purposes of this study. 385 
 386 
3.7 Dissolution studies of AmB in biorelevant media  387 
3.7.1 Sample and separation method (bottle/stirrer) 388 
The AmB dissolution profiles in biorelevant media (KRB with the addition of BSA 1.5 - 4 389 
%w/v) obtained with the bottle/stirrer setup are presented in Figure 5. Dissolution studies were 390 
performed in KRB without BSA, however neither the AmB dissolution nor the AmB 391 
degradation could be quantified due to the very low solubility, and hence minimal dissolution, 392 
of the drug in this medium. The AmB dissolution with its degradation occurring simultaneously 393 
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is similar at both agitation levels with a plateau value ranging from 18.55%-23.14% (low 394 
agitation) and 16.21%-20.50% (high velocity). A drop in the % dissolved is observed at 24h 395 
due to the degradation, with this being higher for the low agitation conditions and the low levels 396 
of BSA (1.5% w/v and 2% w/v) (Figure 5a and 5b). When the dissolution profiles are corrected 397 
for the degradation (Figure 5c and 5d) the continuous dissolution of AmB in the media with 398 
high levels of BSA (3% w/v and 4% w/v) in both agitation conditions can be observed. At low 399 
agitation conditions and at low levels of BSA in the medium the % dissolved from 12h to 24h 400 
is decreased (5.49% in the medium with 1.5% w/v BSA) or remains unchanged (in the medium 401 
with 2% w/v BSA). The dissolution of AmB corrected for degradation is described by a first 402 
order process and the calculated dissolution rate constants are presented in Table 5. There is a 403 
statistically significant decrease in dissolution rate constant (𝑘𝑑𝑖𝑠𝑠) between the same levels of 404 
BSA (2% w/v) in high agitation conditions compared to low agitation conditions (p = 0.033). 405 
While there is a trend towards a decrease in 𝑘𝑑𝑖𝑠𝑠 with increase in BSA concentration in the 406 
medium in low agitation conditions, the differences in 𝑘𝑑𝑖𝑠𝑠 between each medium in the same 407 
agitation conditions were not statistically significant (p > 0.05). The maximum % AmB 408 
dissolved (𝑋𝑚𝑎𝑥) is statistically similar between the same levels of BSA in the two agitation 409 
conditions (p > 0.05). 𝑋𝑚𝑎𝑥 increases with a higher concentration of BSA in the medium, with 410 
this increase being statistically significant only for the low level of BSA (1.5% w/v) when 411 
compared to the other three levels of BSA under low agitation (p < 0.05) (in agreement with 412 
the mass balance studies). For the different levels of BSA under high agitation statistically 413 
significant differences in 𝑋𝑚𝑎𝑥 were not observed (p > 0.05). These results suggest that 414 
agitation rate is of greater relevance when using media with lower albumin concentrations 415 
probably due to the better powder dispersal and its exposure to the albumin that is present. 416 
When the high agitation is applied, the discriminatory ability of the test is reduced.  417 
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The simulated dissolution profiles of AmB in media with different levels of BSA and under 418 
both agitation conditions in the bottle/stirrer setup are presented in Figure 6. The use of a 419 
biexponential function in which the dissolution (𝑘𝑑𝑖𝑠𝑠) and degradation rate (𝑘𝑑𝑒𝑔) constants 420 
were incorporated results in successful prediction of AmB dissolution. Dissolution modeling 421 
could be a valuable tool to provide a mechanistic understanding of drug dissolution in cases 422 
where other processes, such as degradation, occur simultaneously with dissolution.  423 
 424 
3.7.2 Continuous Flow method (flow through cell apparatus) 425 
AmB dissolution profiles in KRB with BSA 2% w/v and BSA 4% w/v under low and high 426 
velocity conditions with the flow through cell apparatus are presented in Figure 7. The 427 
dissolution of AmB was very low in all cases, with the maximum % dissolved being 3.10 ± 428 
0.08 % dissolved in the medium with BSA 4% w/v under low velocity after 8h and the samples’ 429 
concentrations did not reach the corresponding AmB solubility in the medium (Figure 4). A 430 
low % AmB dissolved was also observed in the case where a lower amount of AmB was used 431 
(0.5mg; data not shown) revealing that the low dissolution does not relate to the AmB amount 432 
in the cell. The AmB dissolution with the flow through set up was lower than the AmB 433 
dissolution with the bottle/stirrer set up (Figure 5). The theoretical average linear velocities, 434 
based on flow rate and cell diameter, employed in the flow through cell apparatus were 0.07 435 
cm/s (low velocity) and 0.52 cm/s (high velocity) while the outer edge of the stirrer in the bottle 436 
had a rotational linear velocity of 10.2 cm/s (low agitation) and 29.5 cm/s (high agitation). With 437 
the lowest velocity in the bottle/stirrer setup being at least 20 times greater than the highest 438 
velocity of the flow-through cell apparatus, the reduced AmB power dispersal leading to 439 
aggregation in the flow through cell compared to the bottle/stirrer set up is evident. As the 440 
AmB binding to BSA is a dynamic process, selection of appropriate hydrodynamics which 441 
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facilitate interaction between BSA and solute, which in this case is a poor soluble compound 442 
with wetting issues [41], is essential. 443 
 444 
4. Conclusions 445 
AmB is used for the treatment of systemic fungal infections and it is highly bound to plasma 446 
proteins, including albumin. In clinical practice, AmB is used in patient cohorts that frequently 447 
exhibit hypoalbuminaemia. As hypoalbuminaemia is known to affect pharmacokinetics of 448 
highly protein bound drugs, AmB is a useful model compound to explore the development of 449 
dissolution tests that closely simulate in vivo conditions for parenteral therapies. In this work, 450 
we have developed biorelevant dissolution media with BSA concentrations representing 451 
hypoalbuminaemic patients and healthy subjects. BSA was shown to be a critical component 452 
in the media as the solubility and the degradation rate constant of AmB were dependent on the 453 
concentration of BSA. Accounting for concurrent degradation, dissolution over time could be 454 
modeled and simulated with the proposed approach (Equation 4-6), facilitating calculation of 455 
the total amount of AmB dissolved. The results of the two different setups for dissolution 456 
showed that the AmB powder needed a strong agitation (in terms of average linear velocity) 457 
for dissolution. Following correction of AmB dissolution to account for degraded AmB, a 458 
difference can be observed between the dissolution profiles (dependent on the BSA 459 
concentration), which is reflected in the values of the dissolution rate and maximum amount 460 
dissolved. Conversely, in the high agitation conditions, there was reduced discrimination 461 
between dissolution profiles following correction of dissolution for degraded AmB. 462 
Furthermore, the microbiological studies support the observation that the AmB is solubilised 463 
by binding to BSA, reducing the free fraction for activity and increasing the observed MIC. 464 
Establishing discriminating test methods with BSA present in the dissolution media supports 465 
future development of both biorelevant and clinically relevant tests for parenteral formulations. 466 
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For biorelevant dissolution testing for poorly soluble, highly protein bound drugs such as AmB, 467 
protein concentration should be considered as a medium component and the concentration used 468 
is critical, particularly given the relevance of the concentrations to target patient populations. 469 
Going forward it is important to include this element in biorelevant dissolution test 470 
development for release of AmB from lipid based formulations.  471 
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Tables 587 
Table 1. Composition and physicochemical properties of healthy human plasma and KRB; 588 
Mean ± SD of measured physicochemical properties with different concentrations of BSA (n 589 
= 3). 590 
Ion 
Healthy Human Plasma KRB 
Composition (Concentration (mM); [21 - 23]) 
HCO3
- 24.80 14.99 
K+ 4.60 4.56 
Cl- 99.00 127.32 
Na+ 150.00 136.17 
Ca2+ 4.70 1.00 
Mg2+ 1.60 0.49 
Inorganic phosphorus 1.51 2.00 
D-Glucose 5.60 10.00 
 Physicochemical properties 
pH 7.40 [21] 
7.34 ± 0.03 (+BSA 1.5% w/v) 
7.35 ± 0.03 (+BSA 2.0% w/v) 
7.34± 0.03 (+BSA 3.0% w/v) 
7.36 ± 0.01 (+BSA 4.0% w/v) 
Osmolality (mOsm/L) 289.0 [21] 
298.0 ± 10.4 (+BSA 2.0% w/v) 
308.7 ± 2.5 (+BSA 4.0% w/v) 
Viscosity (cps) 3.8 – 4.7  cP at 22°C [24] 
Measurement at 25°C 
3.70 ± 0.03 (+BSA 1.5% w/v) 
3.79 ± 0.03 (+BSA 2.0% w/v) 
3.88 ± 0.02 (+BSA 3.0% w/v) 
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3.98 ± 0.02 (+BSA 4.0% w/v) 
 591 
Table 2. AmB degradation rate constants (𝑘𝑑𝑒𝑔) and solubility values in KRB with different 592 
BSA concentrations (Mean ± SD; n = 3). 593 
KRB-BSA (%w/v) 𝑘𝑑𝑒𝑔 (h
–1) Solubility (μg/mL) 
1.5 0.03 ± 0.01 13.03 ± 1.09 
2.0 0.07 ± 0.00 13.80 ± 1.40 
3.0 0.07 ± 0.00 15.28 ± 0.78 
4.0 0.10 ± 0.02 17.56 ± 0.82 
 594 
 595 
 596 
 597 
Table 3. Percentage of AmB in mass balance studies in KRB – BSA media after 24 h at 37°C 598 
(Mean ± SD; n = 3). 599 
 KRB BSA 2% w/v KRB BSA 4% w/v 
𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ 39.43 ± 11.09 34.46 ± 4.29 
𝐴𝑚𝐵 𝑓𝑖𝑛𝑎𝑙 76.61 ± 7.98 59.21 ± 2.15 
𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 37.18 ± 3.11 24.75 ± 6.20 
𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 62.82 ± 3.11 75.25 ± 6.20 
𝐴𝑚𝐵 𝑇𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑 23.39 ± 7.98 40.79 ± 2.15 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
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Table 4. MIC and MFC (μg/mL) of AmB against Candida albicans in SBD broth and KRB 607 
supplemented with BSA (n = 2). 608 
Condition 
MIC (μg/mL) 
SBD-BSA 2%w/v SBD-BSA 4%w/v KRB-BSA 2%w/v KRB-BSA 4%w/v 
Control 0.2 – 0.4 
AmB 3 – 4.5 6.4 4.5 7.5 
Condition 
MFC (μg/mL) 
SBD-BSA 2%w/v SBD-BSA 4%w/v KRB-BSA 2%w/v KRB-BSA 4%w/v 
Control 0.8 
AmB > 10.5 > 12.0 > 10.5 > 12.0 
MIC: minimal inhibitory concentration, MFC: minimal fungicidal concentration 609 
 610 
 611 
Table 5. Dissolution rate constants (𝑘𝑑𝑖𝑠𝑠), maximum corrected AmB % dissolved (𝑋𝑚𝑎𝑥) and 612 
goodness of fit parameters (first order curve fitting; R2, AIC) for the dissolution studies with 613 
the bottle/stirrer setup (Mean ± SD; n = 3).  614 
 615 
KRB-BSA (% w/v) 
Agitation 
velocity 
𝑘𝑑𝑖𝑠𝑠  (h
-1) 𝑋𝑚𝑎𝑥 (%) 
R2 AIC 
1.5 Low 0.46 ± 0.10 26.73 ± 1.52 0.93 ± 0.01 28.93 ± 1.56 
2.0 Low 0.30 ± 0.13 34.85 ± 3.29 0.98 ± 0.01 20.20 ± 3.62 
3.0 Low 0.25 ± 0.10 38.33 ± 2.81 0.95 ± 0.02 32.16 ± 4.28 
4.0 Low 0.20 ± 0.03 40.05 ± 3.98 0.95 ± 0.02 33.53 ± 8.04 
2.0 High 0.16 ± 0.02 36.54 ± 1.25 0.99 ± 0.00 13.71 ± 2.20 
4.0 High 0.16 ± 0.02 37.20 ± 5.43 0.95 ± 0.01 28.71 ± 4.57 
R2: correlation coefficient, AIC: Akaike Information Criterion. 616 
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Figure 1. Representative UV spectra of AmB and deg-AmB.  621 
Figure 2. Mass spectra of AmB and deg-AmB in KRB-BSA 4% w/v obtained by LCMS in 622 
negative mode. 623 
Figure 3. ln AmB concentration as a function of time in KRB with BSA 1.5-4 %w/v with the 624 
bottle/stirrer set up (130 rpm) at 37°C (degradation study; Mean ± SD; n=3).  625 
Figure 4. AmB concentration as a function of time in KRB with BSA 1.5-4 %w/v with the 626 
bottle/stirrer set up (130 rpm) at 37°C (solubility study; Mean ± SD; n=3).  627 
Figure 5. % AmB dissolved in KRB with different concentrations of BSA (%w/v) with the 628 
bottle/stirrer set up at 37°C a) and b) dissolution profiles before correction for degradation; c) 629 
and d) dissolution profiles after correction for degradation. (Mean ± SD; n=3) [LA: low 630 
agitation; HA: high agitation]. 631 
Figure 6. Simulated and observed % AmB dissolved as a function of time [lines: simulated 632 
profiles (obtained with Eq 6); points observed values (Mean ± SD; n=3)] 633 
Figure 7. % AmB dissolved in KRB with different concentrations of BSA (%w/v) with the 634 
flow through cell apparatus at 37°C (Mean ± SD; n=3) [LV: low velocity; HV: high velocity]. 635 
 636 
 637 
 638 
 639 
  640 
29 
 
 641 
 642 
 643 
Figure 1 644 
  645 
30 
 
 646 
 647 
Figure 2 648 
  649 
31 
 
 650 
 651 
Figure 3 652 
  653 
32 
 
 654 
 655 
Figure 4 656 
  657 
33 
 
 658 
 659 
Figure 5 660 
  661 
34 
 
 662 
 663 
Figure 6 664 
  665 
35 
 
 666 
 667 
Figure 7 668 
